Looks like the relationship with EBOS is benefiting both parties.
Symbion (which EBOS acquired in 2013) is 40% owned by Zuellig.
MedAdvisors tentacles are growing.
2019 should be a cracker with opportunities now across 3 continents.
And all 3 being multiples in size to Australia.
Ann: MedAdvisor to launch in Asia with Zuellig Pharma, page-4
Add MDR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.5¢ |
Change
-0.005(1.72%) |
Mkt cap ! $215.0M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 29.0¢ | 27.5¢ | $84.31K | 299.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 209547 | 28.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 94066 | 1 |
View Market Depth
| Last trade - 12.52pm 15/11/2024 (20 minute delay) ? |
| MDR (ASX) Chart |
